Actively Recruiting
Phase II Trial of Cemiplimab With or Without Fianlimab Plus Pemetrexed-Platinum Chemotherapy for Patients With Untreated Unresectable Pleural Mesothelioma
Led by Intergroupe Francophone de Cancerologie Thoracique · Updated on 2026-08-11
126
Participants Needed
37
Research Sites
69 weeks
Total Duration
AI-Summary
What This Trial Is About
This trial focuses on patients with treatment-naive, unresectable malignant pleural mesothelioma PM. It is a multicenter, phase IIR, randomized study evaluating two immunotherapy combinations alongside chemotherapy. The purpose is to assess the activity and safety of combining anti-LAG3 and anti-PD-1 immunotherapies with pemetrexed and platinum-based chemotherapy, providing new treatment options for this condition. Participants are randomly assigned to one of two treatment arms. One group receives cemiplimab 350 mg every 3 weeks for up to 24 months, combined with pemetrexed and a platinum agent cisplatin or carboplatin for six 21-day cycles. The other group receives cemiplimab 350 mg plus fianlimab 1600 mg every 3 weeks for up to 24 months, with the same chemotherapy regimen. Treatment continues until disease progression, unacceptable side effects, withdrawal, or a maximum of 2 years of immunotherapy. During the study, participants undergo regular assessments including imaging scans to measure tumor response, safety evaluations, and quality of life questionnaires. Researchers monitor progression-free survival, overall survival, and treatment tolerance throughout the treatment and for up to two years after starting therapy. Follow-up continues after treatment ends to track long-term outcomes and safety.
CONDITIONS
Brief Title
Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma
Research Team
C
Contact IFCT
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here